<DOC>
	<DOC>NCT01245634</DOC>
	<brief_summary>This randomized double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in the prevention of saphenous vein graft disease in patients undergoing elective or urgent coronary artery bypass (CABG) surgery. Patients will be randomized to receive either RO4905417 20 mg/kg by intravenous infusion or placebo every 4 weeks for 32 weeks.</brief_summary>
	<brief_title>A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Graft Occlusion, Vascular</mesh_term>
	<criteria>Adult patients, &gt; 18 and &gt; 85 years of age Patients undergoing primary multivessel CABG with at least one saphenous vein graft. with or without cardiopulmonary bypass Body mass index (BMI) &lt;/= 35 kg/m2 Participation in previous studies evaluating RO4905417 Positive for HIV, receiving antiretroviral drugs, or immunosuppressed Acute infection at screening or active chronic infection within 3 months prior to CABG surgery Patients undergoing emergency cardiac surgery for an immediately lifethreatening condition Patients undergoing concomitant valve surgery History of CABG (only patients without prior CABG surgery will be admitted to the study) Left ventricular ejection fraction &lt; 20% History of transient ischemic attack or stroke within the 12 weeks prior to the CABG procedure Significant renal or liver impairment Malignancy diagnosed within the previous 5 years (except for successfully resected basal cell cancer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>